Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
29
GDTC Quote, Financials, Valuation and Earnings
Last price:
$1.96
Seasonality move
:
-6.92%
Day range:
$1.71 - $1.80
52-week range:
$1.65 - $4.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
120.01x
P/B ratio:
3.10x
Volume:
11.6K
Avg. volume:
98.7K
1-year change:
-39.18%
Market cap:
$20.8M
Revenue:
$52K
EPS (TTM):
-$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GDTC
CytoMed Therapeutics Ltd.
|
$130K | -$0.04 | -- | -- | -- |
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | -- | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -- | -- | -- |
|
WVE
Wave Life Sciences Ltd.
|
$7.7M | -$0.31 | -78.95% | -36.52% | $19.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GDTC
CytoMed Therapeutics Ltd.
|
$1.77 | -- | $20.8M | -- | $0.00 | 0% | 120.01x |
|
BMGL
Basel Medical Group Ltd.
|
$1.05 | -- | $19.7M | 294.67x | $0.00 | 0% | 2.31x |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MNDR
Mobile-health Network Solutions
|
$1.52 | -- | $1.9M | -- | $0.00 | 0% | 0.14x |
|
WVE
Wave Life Sciences Ltd.
|
$7.49 | $19.80 | $1.3B | -- | $0.00 | 0% | 11.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -0.681 | -- | -- |
|
BMGL
Basel Medical Group Ltd.
|
-- | 0.000 | -- | -- |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | 0.000 | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -0.831 | -- | 2.20x |
|
WVE
Wave Life Sciences Ltd.
|
12.99% | 1.535 | 1.67% | 2.40x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | -- | -- | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -1223.46% | -1223.46% | -- | -- |
|
WVE
Wave Life Sciences Ltd.
|
$5.4M | -$56.4M | -64.6% | -73.8% | -740.71% | -$46.1M |
CytoMed Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns GDTC or BMGL?
Basel Medical Group Ltd. has a net margin of -- compared to CytoMed Therapeutics Ltd.'s net margin of --. CytoMed Therapeutics Ltd.'s return on equity of -- beat Basel Medical Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GDTCCytoMed Therapeutics Ltd.-- -- -- BMGLBasel Medical Group Ltd.-- -- -- -
What do Analysts Say About GDTC or BMGL?
CytoMed Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 182.49%. On the other hand Basel Medical Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CytoMed Therapeutics Ltd. has higher upside potential than Basel Medical Group Ltd., analysts believe CytoMed Therapeutics Ltd. is more attractive than Basel Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings GDTCCytoMed Therapeutics Ltd.0 0 0 BMGLBasel Medical Group Ltd.0 0 0 -
Is GDTC or BMGL More Risky?
CytoMed Therapeutics Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Basel Medical Group Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GDTC or BMGL?
CytoMed Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basel Medical Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoMed Therapeutics Ltd. pays -- of its earnings as a dividend. Basel Medical Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDTC or BMGL?
CytoMed Therapeutics Ltd. quarterly revenues are --, which are smaller than Basel Medical Group Ltd. quarterly revenues of --. CytoMed Therapeutics Ltd.'s net income of -- is lower than Basel Medical Group Ltd.'s net income of --. Notably, CytoMed Therapeutics Ltd.'s price-to-earnings ratio is -- while Basel Medical Group Ltd.'s PE ratio is 294.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics Ltd. is 120.01x versus 2.31x for Basel Medical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDTCCytoMed Therapeutics Ltd.120.01x -- -- -- BMGLBasel Medical Group Ltd.2.31x 294.67x -- --
-
Which has Higher Returns GDTC or CUPR?
Cuprina Holdings (Cayman) has a net margin of -- compared to CytoMed Therapeutics Ltd.'s net margin of --. CytoMed Therapeutics Ltd.'s return on equity of -- beat Cuprina Holdings (Cayman)'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GDTCCytoMed Therapeutics Ltd.-- -- -- CUPRCuprina Holdings (Cayman)-- -- -- -
What do Analysts Say About GDTC or CUPR?
CytoMed Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 182.49%. On the other hand Cuprina Holdings (Cayman) has an analysts' consensus of -- which suggests that it could fall by --. Given that CytoMed Therapeutics Ltd. has higher upside potential than Cuprina Holdings (Cayman), analysts believe CytoMed Therapeutics Ltd. is more attractive than Cuprina Holdings (Cayman).
Company Buy Ratings Hold Ratings Sell Ratings GDTCCytoMed Therapeutics Ltd.0 0 0 CUPRCuprina Holdings (Cayman)0 0 0 -
Is GDTC or CUPR More Risky?
CytoMed Therapeutics Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cuprina Holdings (Cayman) has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GDTC or CUPR?
CytoMed Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cuprina Holdings (Cayman) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoMed Therapeutics Ltd. pays -- of its earnings as a dividend. Cuprina Holdings (Cayman) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDTC or CUPR?
CytoMed Therapeutics Ltd. quarterly revenues are --, which are smaller than Cuprina Holdings (Cayman) quarterly revenues of --. CytoMed Therapeutics Ltd.'s net income of -- is lower than Cuprina Holdings (Cayman)'s net income of --. Notably, CytoMed Therapeutics Ltd.'s price-to-earnings ratio is -- while Cuprina Holdings (Cayman)'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics Ltd. is 120.01x versus -- for Cuprina Holdings (Cayman). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDTCCytoMed Therapeutics Ltd.120.01x -- -- -- CUPRCuprina Holdings (Cayman)-- -- -- --
-
Which has Higher Returns GDTC or MNDR?
Mobile-health Network Solutions has a net margin of -- compared to CytoMed Therapeutics Ltd.'s net margin of --. CytoMed Therapeutics Ltd.'s return on equity of -- beat Mobile-health Network Solutions's return on equity of -1223.46%.
Company Gross Margin Earnings Per Share Invested Capital GDTCCytoMed Therapeutics Ltd.-- -- -- MNDRMobile-health Network Solutions-- -- $4.1M -
What do Analysts Say About GDTC or MNDR?
CytoMed Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 182.49%. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 20952.63%. Given that Mobile-health Network Solutions has higher upside potential than CytoMed Therapeutics Ltd., analysts believe Mobile-health Network Solutions is more attractive than CytoMed Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings GDTCCytoMed Therapeutics Ltd.0 0 0 MNDRMobile-health Network Solutions0 0 0 -
Is GDTC or MNDR More Risky?
CytoMed Therapeutics Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GDTC or MNDR?
CytoMed Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoMed Therapeutics Ltd. pays -- of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDTC or MNDR?
CytoMed Therapeutics Ltd. quarterly revenues are --, which are smaller than Mobile-health Network Solutions quarterly revenues of --. CytoMed Therapeutics Ltd.'s net income of -- is lower than Mobile-health Network Solutions's net income of --. Notably, CytoMed Therapeutics Ltd.'s price-to-earnings ratio is -- while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics Ltd. is 120.01x versus 0.14x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDTCCytoMed Therapeutics Ltd.120.01x -- -- -- MNDRMobile-health Network Solutions0.14x -- -- --
-
Which has Higher Returns GDTC or WVE?
Wave Life Sciences Ltd. has a net margin of -- compared to CytoMed Therapeutics Ltd.'s net margin of -707.83%. CytoMed Therapeutics Ltd.'s return on equity of -- beat Wave Life Sciences Ltd.'s return on equity of -73.8%.
Company Gross Margin Earnings Per Share Invested Capital GDTCCytoMed Therapeutics Ltd.-- -- -- WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M -
What do Analysts Say About GDTC or WVE?
CytoMed Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 182.49%. On the other hand Wave Life Sciences Ltd. has an analysts' consensus of $19.80 which suggests that it could grow by 164.35%. Given that CytoMed Therapeutics Ltd. has higher upside potential than Wave Life Sciences Ltd., analysts believe CytoMed Therapeutics Ltd. is more attractive than Wave Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings GDTCCytoMed Therapeutics Ltd.0 0 0 WVEWave Life Sciences Ltd.13 1 0 -
Is GDTC or WVE More Risky?
CytoMed Therapeutics Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Wave Life Sciences Ltd. has a beta of -1.719, suggesting its less volatile than the S&P 500 by 271.88%.
-
Which is a Better Dividend Stock GDTC or WVE?
CytoMed Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wave Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoMed Therapeutics Ltd. pays -- of its earnings as a dividend. Wave Life Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GDTC or WVE?
CytoMed Therapeutics Ltd. quarterly revenues are --, which are smaller than Wave Life Sciences Ltd. quarterly revenues of $7.6M. CytoMed Therapeutics Ltd.'s net income of -- is lower than Wave Life Sciences Ltd.'s net income of -$53.9M. Notably, CytoMed Therapeutics Ltd.'s price-to-earnings ratio is -- while Wave Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics Ltd. is 120.01x versus 11.43x for Wave Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDTCCytoMed Therapeutics Ltd.120.01x -- -- -- WVEWave Life Sciences Ltd.11.43x -- $7.6M -$53.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 60.69% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 7.84% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.82% over the past day.
